Beijing Tiantan Biological Products Corp Ltd: Financial Overview and Market Position
Beijing Tiantan Biological Products Corp Ltd, a prominent player in the health care biotechnology sector, has been making significant strides in the market. Listed on the Shanghai Stock Exchange, the company specializes in the research, development, and commercialization of biological products, with a primary focus on hepatitis treatments and vaccines, including hepatitis and rubella vaccines.
As of July 17, 2025, the company’s close price stood at 19.89 CNH, with a market capitalization of 39,010,000,000 CNH. The 52-week high was recorded at 27.6 CNH on October 7, 2024, while the 52-week low was 18.88 CNH on June 22, 2025. The price-to-earnings ratio was noted at 26.58, reflecting investor sentiment and market expectations.
Recent Market Movements and Fund Involvement
Recent financial news highlights the involvement of Beijing Tiantan Biological Products Corp Ltd in various AI-managed funds, indicating a growing interest from institutional investors. Notably, the company is among the top ten holdings in several AI-managed funds, including:
鹏扬景沣六个月混合A: This fund reported a second-quarter profit of 478.67 million yuan in 2025, with a net value growth rate of 0.98%. The fund’s strategy involved maintaining a neutral stock position while reducing exposure to real estate, automotive, and oil sectors, and increasing positions in non-banking, pharmaceuticals, and transportation sectors.
鹏扬景恒六个月混合A: With a second-quarter profit of 131.7 million yuan in 2025 and a net value growth rate of 1.02%, this fund also adjusted its portfolio to favor non-banking, pharmaceuticals, and transportation sectors.
鹏扬景明一年混合: This fund achieved a second-quarter profit of 459.17 million yuan in 2025, with a net value growth rate of 1.35%. The fund’s strategy included maintaining a neutral stock position and focusing on sectors with stable growth potential, such as consumer goods, pharmaceuticals, and financial services.
These funds, managed by Yang Aibin, have shown positive performance over the past year, with Beijing Tiantan Biological Products Corp Ltd being a significant component of their portfolios.
Strategic Focus and Future Outlook
Beijing Tiantan Biological Products Corp Ltd continues to focus on its core competencies in biotechnology, particularly in the development of vaccines and treatments for hepatitis. The company’s strategic positioning in the market, coupled with its inclusion in prominent AI-managed funds, underscores its potential for sustained growth and innovation.
For more detailed information about the company and its offerings, interested parties can visit their official website at www.btbp.com.cn .
As the company navigates the evolving landscape of the biotechnology sector, its commitment to research and development remains a cornerstone of its strategy, promising continued advancements and contributions to public health.